Hong Kong · Delayed Price · Currency is HKD VISEN Pharmaceuticals Statistics
Total Valuation
HKG:2561 has a market cap or net worth of HKD 3.51 billion. The enterprise value is 2.62 billion.
| Market Cap | 3.51B |
| Enterprise Value | 2.62B |
Important Dates
The next estimated earnings date is Thursday, April 30, 2026.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2561 has 105.02 million shares outstanding. The number of shares has increased by 3.43% in one year.
| Current Share Class | 105.02M |
| Shares Outstanding | 105.02M |
| Shares Change (YoY) | +3.43% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.18% |
| Owned by Institutions (%) | n/a |
| Float | 21.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3,804.04 |
| PB Ratio | 3.74 |
| P/TBV Ratio | 3.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.05 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -13.28 |
Financial Position
The company has a current ratio of 22.99, with a Debt / Equity ratio of 0.00.
| Current Ratio | 22.99 |
| Quick Ratio | 21.38 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -1,820.18 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -23.40% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 17,066 |
| Profits Per Employee | -4.40M |
| Employee Count | 54 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 34.97 |
| 200-Day Moving Average | 41.51 |
| Relative Strength Index (RSI) | 44.85 |
| Average Volume (20 Days) | 31,230 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2561 had revenue of HKD 921,551 and -237.56 million in losses. Loss per share was -2.45.
| Revenue | 921,551 |
| Gross Profit | 921,551 |
| Operating Income | -219.40M |
| Pretax Income | -237.56M |
| Net Income | -237.56M |
| EBITDA | -219.38M |
| EBIT | -219.40M |
| Loss Per Share | -2.45 |
Balance Sheet
The company has 883.10 million in cash and 1.31 million in debt, with a net cash position of 881.79 million or 8.40 per share.
| Cash & Cash Equivalents | 883.10M |
| Total Debt | 1.31M |
| Net Cash | 881.79M |
| Net Cash Per Share | 8.40 |
| Equity (Book Value) | 937.50M |
| Book Value Per Share | 8.93 |
| Working Capital | 911.08M |
Cash Flow
In the last 12 months, operating cash flow was -197.50 million and capital expenditures -128,206, giving a free cash flow of -197.63 million.
| Operating Cash Flow | -197.50M |
| Capital Expenditures | -128,206 |
| Free Cash Flow | -197.63M |
| FCF Per Share | -1.88 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -23,807.38% |
| Pretax Margin | -25,777.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:2561 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.43% |
| Shareholder Yield | -3.43% |
| Earnings Yield | -6.78% |
| FCF Yield | -5.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HKG:2561 has an Altman Z-Score of 70.8 and a Piotroski F-Score of 2.
| Altman Z-Score | 70.8 |
| Piotroski F-Score | 2 |